Our findings in a cross-sectional cohort of individuals with RA and controls suggest that IL-21 based therapies for RA may be more efficacious if targeted to individuals with increased IL-21R expression on memory B cells; studies that evaluate response to therapy, requiring a longitudinal cohort with samples collected before and after initiation of therapy would be of particular interest. Here, IL21R is linked to rheumatoid arthritis.